🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

5 recruiting trials

for Complement 3 Glomerulopathy

Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS NCT05795140Phase 39 sites📍 São Paulo📍 Rio de Janeiro📍 Beijing Novartis Pharmaceuticals · Tests: Iptcaopan 200 mg Chinese Adults With Kidney Disease NCT07522099Phase 29 sites📍 Shenzhen📍 Guiyang📍 Zhengzhou ADARx Pharmaceuticals, Inc. · Tests: ADX-038, Telitacicept A Study of Complement 3 Glomerulopathy (C3G) Patients Treated With Iptacopan Through an Early Access Program in Spain NCT07598448n/a2 sites📍 Córdoba📍 Madrid Novartis Pharmaceuticals A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G NCT06419205Phase 24 sites📍 Hollywood📍 Lawrenceville📍 Orangeburg Akebia Therapeutics · Tests: ADX-097 Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. NCT04817618Phase 387 sites📍 Aurora📍 Miami📍 Lawrenceville Novartis Pharmaceuticals · Tests: Placebo, iptacopan
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy